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Burkholderia pseudomallei is a tier 1 select agent, and the causative agent of melioidosis, a disease with effects ranging from
chronic abscesses to fulminant pneumonia and septic shock, which can be rapidly fatal. Autotransporters (ATs) are outer mem-
brane proteins belonging to the type V secretion system family, and many have been shown to play crucial roles in pathogenesis.
The open reading frame Bp1026b_II1054 (bcaA) in B. pseudomallei strain 1026b is predicted to encode a classical autotrans-
porter protein with an approximately 80-kDa passenger domain that contains a subtilisin-related domain. Immediately 3= to
bcaA is Bp11026_II1055 (bcaB), which encodes a putative prolyl 4-hydroxylase. To investigate the role of these genes in patho-
genesis, large in-frame deletion mutations of bcaA and bcaB were constructed in strain Bp340, an efflux pump mutant derivative
of the melioidosis clinical isolate 1026b. Comparison of Bp340bcaA and Bp340bcaB mutants to wild-type B. pseudomallei in
vitro demonstrated similar levels of adherence to A549 lung epithelial cells, but the mutant strains were defective in their ability
to invade these cells and to form plaques. In a BALB/c mouse model of intranasal infection, similar bacterial burdens were ob-
served after 48 h in the lungs and liver of mice infected with Bp340bcaA, Bp340bcaB, and wild-type bacteria. However, signif-
icantly fewer bacteria were recovered from the spleen of Bp340bcaA-infected mice, supporting the idea of a role for this AT in
dissemination or in survival in the passage from the site of infection to the spleen.
Burkholderia pseudomallei is a Gram-negative saprotroph thatcauses melioidosis, a disease that ranges from chronic ab-
scesses to fulminant pneumonia and septic shock and which can
be rapidly fatal. B. pseudomallei has an approximately 7.2-Mb ge-
nome divided into two chromosomes (1), affording this bacte-
rium the metabolic repertoire necessary to adapt to and survive in
a variety of different habitats, including soil, the rhizosphere of
plants, and a wide variety of human and nonhuman mammals (2).
Melioidosis, first reported by A. Whitmore, an army pathologist
working in Burma, in 1912 (3), emerged as an infectious disease of
serious public health concern in the latter part of the 20th century,
manifesting as a rapidly progressing septicemia, with or without
pneumonia; a localized soft tissue infection; or a subclinical infec-
tion with delayed evidence of clinical infection (4, 5). Southeast
Asia and northern Australia are areas of B. pseudomallei endemic-
ity; however, sporadic B. pseudomallei infections have been re-
ported worldwide (6), including but not limited to the United
States, Puerto Rico, El Salvador, and Brazil (4, 7–9). B. pseudomal-
lei is classified as an NIH category B priority pathogen and select
agent (10), and has recently been reclassified as a CDC tier 1 select
agent due to its virulence in animals, low infectious dose, robust
environment stability, and possible delay in diagnosis, since the
United States is not an area of B. pseudomallei endemicity (http:
//www.selectagents.gov).
Autotransporters (ATs) are outer membrane proteins belong-
ing to the type V secretion system (T5SS) family, the largest family
of extracellular proteins in Gram-negative bacteria (11). These
proteins have been shown to function as adhesins, degradative
enzymes, and cytotoxins, as well as having roles in cell-to-cell
spread and serum resistance (12). The AT family is divided into
classical and trimeric proteins. The C-terminal 250 to 300 amino
acids (aa) of classical ATs form a -barrel that is inserted into the
outer membrane, where it facilitates the translocation of the N-
terminal passenger domain to the cell surface. Trimeric ATs re-
quire three proteins to form a functional unit, with the 67 to 76
C-terminal amino acids of each monomer contributing one-third
of the barrel (13). The -barrel domains of AT proteins are well
conserved, while the passenger domains can differ substantially
and have distinct functions (14).
To date, little is known about how B. pseudomallei causes dis-
ease (15). It is able to invade and replicate in phagocytic and
nonphagocytic cells, and following type III secretion system
(T3SS)-mediated endosomal escape, B. pseudomallei replicates in
the cytoplasm of eukaryotic cells and spreads from cell to cell
without leaving the cytoplasm (16, 17). One B. pseudomallei type
VI secretion system (T6SS) has been shown to mediate multinu-
cleated giant cell (MNGC) formation (18), allowing the bacteria
to freely spread from cell to cell by actin-mediated motility,
similar to Shigella flexneri and Listeria monocytogenes (19). B. pseu-
domallei actin-dependent motility requires the trimeric auto-
transporter BimA, which contains proline-rich motifs and WH2-
like domains that are believed to be responsible for actin
polymerization at the pole of the bacterial cell where BimA is
localized (20).
The genome of B. pseudomallei strain 1026b contains genes
predicted to encode nine trimeric ATs and two classical ATs. The
purpose of this study was to determine the role of the predicted
classical AT encoded by Bp1026b_II1054 in pathogenesis.
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MATERIALS AND METHODS
Bacterial strains. All manipulations of B. pseudomallei were conducted in
a CDC/USDA-approved animal biosafety level 3 (ABSL3) facility at the
University of North Carolina at Chapel Hill. The bacterial strains used in
this study are listed in Table 1. B. pseudomallei strains were cultured in
low-salt lysogeny broth (LSLB) or on low-salt lysogeny broth agar
(LSLBA) (Sigma-Aldrich, St. Louis, MO) for 24 h at 37°C. Escherichia coli
strains were cultured on LB or LB agar (LBA). When appropriate, culture
media were supplemented with kanamycin (Km; 125 g/ml for B. pseu-
domallei and 50 g/ml for E. coli) or with Zeocin (Zeo; 100 g/ml for B.
pseudomallei and 35 g/ml for E. coli). LB agar was supplemented with 400
g/ml of diaminopimelic acid (DAP [LL-, DD-, and mesoisomers]; Sigma-
Aldrich, St. Louis, MO) to support growth of RHO3 cells. Yeast extract-
tryptone (YT) medium containing 10 g/liter of yeast extract (Difco, De-
troit, MI) and 10 g/liter of tryptone (Fisher Scientific, Fairlawn, NJ)
supplemented with 15% sucrose and X-Gluc (5-bromo-4-chloro-3-indo-
lyl--D-glucuronic acid; GoldBio, St. Louis, MO) was used for counterse-
lection during the construction of B. pseudomallei deletion mutation
strains.
Construction of B. pseudomallei bcaA and bcaB mutant strains and
plasmids. Deletion of the bcaA and bcaB genes from B. pseudomallei strain
Bp340 [a derivative of strain 1026b containing a (amrRAB-oprA) muta-
tion; the strain was shown by Herbert Schweizer to be as virulent as 1026b
in the BALB/c acute model of infection] (22, 24) was carried out by allelic
exchange using pEXKm5 (21) derivatives. The DNA fragments used to
construct pCCX1 and pCCX2 (Table 1) were generated using a two-step,
overlap PCR method and cloned into pEXKm5. DNA fragments con-
tained approximately 500 bp 5= to the gene, including the first three
codons, and 500 bp 3= to the gene, including the last three codons. pCCX1
and pCCX2 were transformed into E. coli RHO3 cells, and were delivered
to Bp340 by conjugation. For Bp340bcaA and Bp340bcaB complemen-
tation strains, the gene and promoter region were cloned into pUC18T-
mini-Tn7-Zeo and delivered as previously described (25). All plasmids
were verified to be correct and to contain no unintended nucleotide
changes by DNA sequence analysis.
Bacterial conjugations. Matings between B. pseudomallei and E. coli
strain RHO3 were performed by incubating Bp340 with RHO3 cells car-
rying the appropriate allelic exchange plasmid (Table 1) on LSLB-DAP
agar plates overnight. Cointegrants were selected on LSLB-Km. PCR-con-
firmed cointegrants were grown overnight in LSLB without selection, al-
lowing for a second recombination event and the loss of the allelic ex-
change plasmid. Colonies were selected on YT agar supplemented with
15% sucrose and X-Gluc (21), as previously described. Colonies were
screened by PCR for the deletion mutation, and the strains were con-
firmed by DNA sequencing. To generate the complementation strains,
RHO3 cells harboring pCCZ1 or pCCZ2 (Table 1) were mated with the
Bp340bcaA strain and the Bp340bcaB strain, respectively, and cointe-
grants were selected on LSLB-Zeo (25). Integration at the correct location
was confirmed by PCR. All DNA regions encompassing about 2 kb across
the deletion junction were PCR amplified and verified to be correct and to
contain no unintended nucleotide changes by DNA sequence analysis.
DNA sequences inserted into the att Tn7 site in complementation strains
were also PCR amplified and verified by DNA sequence analysis.
Total RNA isolation and cDNA synthesis. Total RNA was isolated in
TRIzol (Invitrogen, Grand Island, NY) from Bp340 grown overnight in
LSLB at 37°C according to the manufacturer’s protocol. For the reverse
transcription (RT) step, 5 ng of total RNA was transcribed using Super-
Script III reverse transcriptase (Invitrogen, Grand Island, NY) with
oligo(dT) and random primers according to the manufacturer’s instruc-
tions. Transcripts were determined by the use of PCR primers described in
Table 2.
Immunoblot analysis. Strain Bp340::pCCS12HA1 was constructed
using pCCS12HA1, a suicide plasmid containing the constitutively active
ribosomal S12 subunit promoter (PS12) up to and including the S12 ribo-
somal binding site fused to the first 329 codons of bcaA, starting at the
ATG. The hemagglutinin (HA) epitope-encoding sequence was intro-
duced between codons 58 and 59. The plasmid was verified by PCR and
sequence analysis to have integrated into the Bp340 strain 3= to the HA
epitope-encoding sequence, yielding a chromosomal HA-tagged copy of
bcaA driven by the S12 promoter. Whole-cell lysates were prepared from
overnight cultures grown in LSLB-Km. SDS-PAGE was performed by the
method of Laemmli (26) using denaturing 10% SDS polyacrylamide gels.
Gels were transferred to a nitrocellulose membrane (Scheleicher and
Schuell Bioscience, Dassel, Germany) and were probed with an anti-HA
antibody (diluted 1:5,000) followed by an IR800-conjugated secondary
antibody (Rockland, Gilbertsville, PA) (diluted 1:20,000). Antigen-anti-
body complexes were visualized using the Odyssey infrared imaging sys-
tem (Li-Cor Biosciences, Lincoln, NE).
Plaque assay. B. pseudomallei strains were grown overnight in LSLB at
37°C. Each well of a 6-well plate was seeded with A549 human lung cells
such that confluent monolayers contained approximately 1  106 cells per
well. Cells were incubated in F12K (Cellgro, Circle Westwood, MA) sup-
plemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY)
at 37°C with 5% CO2. Bacterial strains were diluted to an optical density at
600 nm (OD600) of 0.1 in fresh tissue culture medium and further diluted
1:10, and 25 l of the diluted culture was added to each well (multiplicity
of infection [MOI] of 0.1). Plates were incubated for 2 h, and each well was
washed thoroughly with fresh culture medium and overlaid with a mix-
ture containing 1.2% low-melting agarose (Fisher Scientific, Fairlawn,
NJ), F12K with 10% FBS, gentamicin (90 g/ml), and 0.01% Neutral red
(Fisher Scientific, Waltham, MA). Plates were incubated for 24 h at 37°C
with 5% CO2, and plaques were enumerated in each well. Experiments
were performed three times in duplicate, and the results were combined.
The combined results were analyzed using a one-way analysis of variance
(ANOVA) with Tukey’s posttest at a 95% confidence interval.
Adherence and invasion assay. Bacterial strains and A549 cells were
grown as described above. Bacteria were diluted to an OD600 of 0.1 in fresh
tissue culture medium, and 250 l of the diluted cultures was added to
TABLE 1 Strains and plasmids used in this study





RHO3 Kms; SM10(pir) asd::FRT aphA::FRT 21
Bp340 1026b with (amrRAB-oprA) 22
Bp340bcaA Bp340 with bcaA This study
Bp340bcaB Bp340 with bcaB This study
Bp340bcaA::attTn7bcaA Bp340 with bcaA::att Tn7 bcaA This study
Bp340bcaB::attTn7bcaB Bp340 with bcaB::att Tn7 bcaB This study
Bp340::pCCS12HA1 Bp340 with pCCS12HA1::bcaA This study
Plasmids
pCCX1 Kmr; pEXKm5 derivative 21
pCCX2 Kmr; pEXKm5 derivative 21
pCCZ1 Ampr, Kmr; pUC18T-mini-Tn7-Zeo
derivative
23
pMBZ2 Ampr, Kmr; pUC18T-mini-Tn7-Zeo
derivative
23
pTNS2 Ampr; plasmid expressing tnsABCD from
Plac
23
pCCS12HA1 Kmr; pCC derivative (pRE118




TABLE 2 Primers used in this study
Primer name Primer sequence
CBcaART_F TTC GACAGC TTC CAT CTC GGC
CBcaART_R GTT CTT CAG ATG CAC ATA CGC GAC
CBcaBRT_F TTT CGC AGA CGT ACT TGA CGC AGC
CBcaBRT_R TTG AAC ATC AGC GTG ATC CGC ATC GTC
CBcaA/BRT_F CTC GGC AAG AAC GGA TGG CTG
CBcaA/BRT_R CAG AAA CCG GTG GAT CTG CGC
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each well (MOI of 100). Plates were incubated for 2 h, and each well was
washed thoroughly with fresh culture medium. For the adherence assay,
cells were immediately lysed using 1% Triton X-100 (Sigma-Aldrich, St.
Louis, MO) and were diluted and plated to determine the total CFU in
each well. For the invasion assay, cells were incubated an additional 1.5 h
with gentamicin (90 g/ml), washed with fresh culture medium, and
lysed using 1% Triton X-100. Lysates were diluted and plated to deter-
mine the total CFU in each well. To calculate the percentage of adherent or
invading bacteria, the number of adherent or invading bacteria was di-
vided by the total number of bacteria in the inoculum and multiplied by
100. Experiments were performed three times in duplicate, and the results
were combined. The combined results were analyzed using a one-way
ANOVA with Tukey’s posttest at a 95% confidence interval.
Animal experiments. All animal experiments were approved by the
Animal Studies Committee of the University of North Carolina at Chapel
Hill (protocol 10-165). Six- to 8-week-old female BALB/c mice (The Jack-
son Laboratory, Bar Harbor, ME) were allowed free access to sterilized
food and water. Animals were anesthetized prior to infection with Avertin
(140 mg/kg of body weight) by intraperitoneal injection. For all infec-
tions, the desired inoculum of B. pseudomallei was suspended in sterile
phosphate-buffered saline (PBS). Mice were inoculated intranasally (i.n.)
with 500 CFU (the 50% lethal dose [LD50] for strain 1026b has been
determined to be around 900 CFU [24]), and at the indicated time points
were euthanized by CO2 overdose. Organs were aseptically harvested and
homogenized, and the bacterial burden of each organ was determined by
plating serial dilutions of the homogenates. Animal experiments were
performed twice, with three to four animals per strain per time point, and
the results were combined. Animal experiments were terminated at 48 h,
at which time all animals had become moribund.
Pathology. Lungs, livers, and spleens of 6- to 8-week-old female
BALB/c mice intranasally infected with 500 CFU of Bp340 or the
Bp340bcaA mutant were harvested and fixed in 10% neutral buffered
formalin for 24 h. Samples were stored in 70% ethanol until processed
into paraffin using routine methods. Paraffin-embedded tissues were di-
vided into sections 3 to 5 m thick, captured onto glass slides, and stained
with hematoxylin and eosin (HE). Sections of liver, spleen, and lung were
analyzed using light microscopy by a single pathologist (L. Borst) who was
blinded with respect to the identity of the group. Microscopic lesions
consisting primarily of necrosis and acute inflammation (neutrophils,
macrophages, apoptotic bodies, and fibrin) were quantified as follows. In
the lung, the affected bronchi per 20 bronchiolar profiles were counted
starting with an affected bronchiole. In the liver and spleen, inflammatory
foci were enumerated in 10 consecutive fields at 20 magnification, start-
ing with an area of inflammation identified at low magnification.
RESULTS
Bioinformatic analysis of the bcaA and bcaB genes of B. pseu-
domallei strain 1026b. Bp1026b_II1054 is a 3,393-bp gene, pre-
dicted to encode a classical AT, that we named bcaA for Burkhold-
eria classical autotransporter A. Forty base pairs 3= to bcaA is
Bp11026_II1055 (which we named bcaB), a 687-bp gene predicted
to encode a hypothetical protein. There is a 480-bp gene predicted
to encode a hypothetical protein 1,522 bp 5= to bcaA, and 198 bp 3=
to bcaB is a 1,593-bp gene oriented in the opposite direction, pre-
dicted to encode a periplasmic solute-binding protein (Fig. 1A).
SignalP identified a signal peptide and a cleavage site on the
predicted 1,133-aa BcaA protein between aa 40 and 41 (27). The
Simple Modular Architecture Research Tool (SMART) predicts
BcaA to have a serine protease domain, from aa 64 to 380, belong-
ing to the peptidase S8 or subtilase family, and a classical AT -do-
main from aa 857 to 1121. BcaB is a 255-aa protein predicted to
contain a prolyl 4-hydroxylase domain from aa 41 to 225 (Fig. 1B)
(28).
BLAST indicated that homologues of bcaA are present in B.
pseudomallei, B. mallei, B. thailandensis, and B. gladioli strains but
not in Ralstonia or Cupriavidus species, close relatives of the Burk-
holderia genus. All B. pseudomallei and B. mallei strains for which
genome sequences are available are predicted to encode proteins
with 99% identity with BcaA, and 89% identity is found in B.
thailandensis and 82% identity in B. oklahomensis. Predicted ho-
mologues are not found in bacteria outside the Burkholderia ge-
nus, suggesting that this gene is unique to Burkholderia.
To investigate the role of bcaA and bcaB in the pathogenesis of
B. pseudomallei, we constructed strains of Bp340 containing in-
frame deletion mutations in each gene (Fig. 1A) by allelic ex-
change (21). Complementation of these deletion mutations was
accomplished by delivering a full-length copy of the gene, along
with its presumed promoter region (the approximately 1-kb re-
gion immediately 5= to the bcaA translation start site), to Tn7 att
sites in the respective deletion strains using pUC18T-mini-Tn7-
Zeo (25). The same presumed promoter region, approximately 1
kb preceding the translation start site of bcaA, was fused to the
full-length copy of bcaB for the construction of the complemen-
tation of the Bp340bcaB strain.
bcaA and bcaB appear to form an operon. RT-PCR was used
to determine if bcaA and bcaB are cotranscribed. cDNA was pre-
pared from strain Bp340 grown overnight at 37°C in LSLB, and
used as the template for PCR using the primer pairs (Table 2)
FIG 1 bcaA and bcaB appear to form an operon. (A) Genetic organization of
the bcaA and bcaB locus and description of the strains used in this study. A
visual representation of the primer pairs used for RT-PCR is shown. (B) The
putative domains of BcaA and BcaB proteins drawn to scale. (C) RT-PCR
analysis of the operon structure of bcaA and bcaB. gDNA, genomic DNA.
Primer pairs 1 and 2, 3 and 4, and 5 and 6 were used as indicated in panel A.
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shown in Fig. 1A. Products of expected sizes were obtained for
each primer pair (Fig. 1C), including the pair spanning the inter-
genic region between bcaA and bcaB, suggesting that these genes
are cotranscribed. No product was observed in the mock RT sam-
ples, demonstrating the lack of DNA contamination in the iso-
lated RNA samples and, consequently, the cDNA samples.
BcaA appears to be proteolyzed to smaller polypeptides. To
visualize the production of BcaA protein, we constructed Bp340
derivatives in which nucleotides encoding HA epitopes were in-
serted either immediately following the protein’s predicted signal
sequence cleavage site or between codons 58 and 59. Both strains
were grown overnight in LSLB at 37°C, but no polypeptide was
recognized by Western blotting using an anti-HA antibody. After
several unsuccessful attempts to visualize the BcaA protein when
the gene was expressed from its native promoter, we constructed a
strain in which bcaA was expressed from a strong, constitutively
active promoter (the promoter for the rpsL gene from Burkhold-
eria pseudomallei 1026b). First, we inserted the HA epitope-en-
coding codons immediately following the predicted signal se-
quence cleavage site, but again were unsuccessful at visualizing
BcaA. Finally, we inserted the HA epitope-encoding codons be-
tween codons 58 and 59 (Bp340::pCCS12HA1) and the protein
was then successfully visualized by Western blot analysis. Poly-
peptides approximately 21 kDa and 28 kDa in size as well as a large
smear between 250 and 75 kDa were observed in whole-cell lysates
of the Bp340::pCC12HA1 strain, but not in whole-cell lysates of
the wild-type strain lacking the HA epitope tag (Fig. 2). These data
suggest that BcaA is proteolyzed to smaller polypeptides. The
smaller polypeptides were not detected in Western blots of con-
centrated supernatant fractions (data not shown), suggesting that
they remain associated with the bacterial cell.
bcaA and bcaB are required for efficient plaque formation. B.
pseudomallei can spread from cell to cell without exiting the cyto-
plasm and can form plaques in a cell monolayer (29). To deter-
mine if bcaA or bcaB contributes to plaque formation, A549 respi-
ratory epithelial cell monolayers were infected at an MOI of 0.1
and plaques were counted after 24 h. The Bp340 strain formed an
average of 100 plaques/well, while the Bp340bcaA strain (Fig.
3A) and the Bp340bcaB strain (Fig. 3B) each formed only about
50 to 60 plaques/well. Complementation of both mutations re-
stored plaque-forming ability to wild-type levels, indicating that
both bcaA and bcaB are required for efficient plaque formation.
bcaA and bcaB are required for efficient invasion of A549
cells. The plaques formed by the Bp340bcaA and Bp340bcaB
strains appeared to be of sizes similar to those formed by wild-type
bacteria, suggesting that bcaA and bcaB are involved in the first
steps of plaque formation and that they are therefore required for
either adhesion or invasion. To determine if bcaA and bcaB are
required for efficient adhesion or invasion, A549 cell monolayers
were infected at an MOI of 100, and following a 2-hour incuba-
tion, cells were either washed, lysed, serially diluted, and plated to
determine percent adhesion, or were washed, incubated with 90
g/ml of gentamicin for an additional 1.5 h, and then lysed, seri-
ally diluted, and plated to determine percent invasion. No differ-
ence in adhesion between the Bp340 and Bp340bcaA strains or
between the Bp340 and Bp340bcaB strains was observed (Fig.
4A). However, the Bp340bcaA and Bp340bcaB strains demon-
strated significantly decreased invasion compared to Bp340 (Fig.
4B), suggesting that bcaA and bcaB are required for efficient inva-
sion of A549 cells. Complementation of bcaA and bcaB at the
Tn7 att site restored invasion to wild-type levels. C57BL/6 bone
marrow-derived macrophages were also used in similar experi-
ments, but no difference was observed between the Bp340,
Bp340bcaA, and Bp340bcaB strains (data not shown). bcaA
and bcaB, therefore, are required for invasion of nonphagocytic
cells, but do not appear to affect uptake by phagocytic cells.
bcaA is required for efficient dissemination to or survival in
the spleen. To determine the contribution of bcaA and bcaB to B.
pseudomallei pathogenesis, we used an acute intranasal (i.n.)
mouse model of infection. Bp340 has been shown to have the same
LD50 as 1026b (24) when delivered by the i.n. route, so 6- to
8-week-old female BALB/c mice were inoculated with 500 CFU of
B. pseudomallei delivered in a 25-l volume to the nose. All ani-
mals showed signs of respiratory distress by 48 h postinoculation,
becoming moribund and marking the endpoint of our experi-
FIG 2 Immunoblot of whole-cell lysates of strain Bp340 with no tag and the
Bp340::pCCS12HA1 strain. Strains were separated by SDS-PAGE and stained
with anti-HA antibody.
FIG 3 Average numbers of plaques formed in an A549 monolayer by Bp340,
the Bp340bcaA strain (A), the Bp340bcaB strain (B), and the respective
complementation strains. Assays were performed three times in duplicate, and
the results were combined. Data are means  standard errors of the means
(SEM). **, P  0.0080; ***, P  0.0001 (by one-way ANOVA with Tukey’s
posttest at a 95% confidence interval).
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ments. The numbers of CFU in the lungs, liver, and spleen were
determined at 48 h postinoculation. The numbers of CFU recov-
ered from the lungs and livers of animals inoculated with Bp340
and the Bp340bcaA mutant were not significantly different. The
number of CFU recovered from the spleen of strain Bp340bcaA-
infected mice, however, was significantly lower than the number
recovered from mice infected with Bp340 (Fig. 5A). Complemen-
tation of bcaA at the Tn7 att site restored bacterial numbers in
the spleen to wild-type levels, suggesting that bcaA is required for
efficient dissemination to or survival of B. pseudomallei infection
in the spleen in this model. The numbers of bacteria recovered
from the lungs, liver, and spleen of animals inoculated with the
Bp340bcaB mutant were not significantly different from those of
animals infected with Bp340 (Fig. 5B).
bcaA does not appear to contribute to B. pseudomallei-in-
duced organ pathology. To determine if bcaA contributes to tis-
sue pathology, lungs, livers, and spleens were harvested at 48 h
post-intranasal inoculation, and hematoxylin and eosin (H&E)-
stained sections were prepared, coded for blind scoring, and ex-
amined for histopathological changes. Inflammation was ob-
served in the lungs, livers, and spleens of all mice infected with the
Bp340 or Bp340bcaA strain, differing only in the degree of sever-
ity. Approximately the same number of affected bronchi per bron-
chiolar profile was found in the mice infected with both strains,
and the numbers of inflammatory foci found in the livers and
spleens were also similar.
Lungs showed suppurative bronchointerstitial pneumonia,
with small airways partially to completely filled with mostly de-
generative neutrophils. Adjacent and randomly scattered alveolar
septa were moderately expanded by degenerative neutrophils and
fibrin (microthrombi). Livers showed multifocoal necrosuppura-
tive hepatitis with random hepatocellular necrosis and inflamma-
tory infiltrate (neutrophils), as well as fibrin hemorrhage. Spleens
showed multifocal necrosuppurative splenitis with scattered (red
pulp) areas of necrosis and inflammatory infiltrate (neutrophilic
predominant, rare macrophages, apoptotic bodies), as well as
mild fibrin hemorrhage.
The overall histological picture was of bronchopneumonia fol-
lowed by acute sepsis as evidenced by interstitial pulmonary in-
volvement and multifocal distribution of inflammation and ne-
crosis in the spleens and livers (Fig. 6); however, there was no
significant difference in histological scoring between organs har-
vested from animals inoculated with strain Bp340 and those from
animals inoculated with strain Bp340bcaA.
DISCUSSION
The sequenced genome of B. pseudomallei contains 11 genes pre-
dicted to encode AT proteins. Only the trimeric AT BimA (20) has
FIG 4 CFU recovered after 2-h adherence and invasion assays with Bp340, the
Bp340bcaA strain (A), the Bp340bcaB strain (B), and the respective com-
plementation strains. Assays were performed three times in duplicate, and the
results were combined. Data are means  SEM. ***, P  0.0001 (by one-way
ANOVA with Tukey’s posttest at a 95% confidence interval).
FIG 5 Six- to 8-week-old female BALB/c mice were inoculated with 500 CFU
of B. pseudomallei Bp340 (white circles), the Bp340bcaA strain (A), the
Bp340bcaB strain (B) (light gray circles), and the respective complementa-
tion strains (dark gray circles). Each circle represents the number of CFU
recovered from a mouse. The horizontal lines represent the average numbers
of CFU. The dashed line represents the lower limit of detection. ***, P 
0.0001. Animal experiments were performed twice for each strain, and the
results were combined.
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been well characterized, and it has been shown to play a role in
pathogenesis. This work focused on the characterization of bcaA, a
gene predicted to encode a classical AT. Our data indicate that
bcaA and bcaB contribute to nonphagocytic cell invasion and bcaA
to dissemination to or survival of B. pseudomallei in the spleen in
a BALB/c intranasal model of infection.
The bcaA and bcaB genes appear to form an operon. RT-PCR
supports this hypothesis by showing that bcaA and bcaB are
cotranscribed from a common promoter upstream of bcaA. Our
data do not rule out the presence of an additional bcaB promoter
located within the bcaA gene. However, the DNA fragment used to
complement the bcaB strain contained approximately 1 kb pre-
ceding the translation start site of bcaA fused directly to the full-
length copy of bcaB and this DNA fragment restored invasion of
the bcaB strain to wild-type levels, further suggesting that bcaA
and bcaB are transcribed from a promoter 5= to bcaA.
BcaA is predicted to be a 113-kDa classical AT protein with an
approximately 80-kDa passenger domain containing a serine pro-
tease domain belonging to the peptidase S8 or subtilase family and
a 30-kDa -domain. Subtilisins are the second largest family of
serine proteases, characterized by a conserved catalytic triad that
functions in a charge relay system much like trypsin family pro-
teases (30). Subtilisins use well-conserved Asp, Ser, and His cata-
lytic residues for their protease activity (31), and their functions
include contributing to cellular nutrition, mediating host cell in-
vasion, and the maturation of other polypeptides (32). A few AT
subtilases have been described, including Ssp from Serratia marc-
escens, a 112-kDa protein with an approximately 80-kDa passen-
ger domain that is autoproteolyzed into a 41-kDa polypeptide that
is released into the medium (33), and AasP from Actinobacillus
pleuropneumoniae, a 104-kDa protein that cleaves another outer
membrane protein (OmlA) into smaller polypeptides of about 30
kDa that are released into the medium (34). BcaA contains the
same well-conserved catalytic triad (Asp 90, His 124, and Ser 329)
found in other subtilisins. Western blot characterization studies
using a HA-tagged BcaA detected 21-kDa and 28-kDa polypep-
tides that were present in whole-cell lysates but not in superna-
tants. Much like Ssp from S. marcescens, the BcaA 80-kDa passen-
ger domain appears to be proteolyzed into smaller polypeptides;
however, these small polypeptides do not appear to be released
into the extracellular environment in the case of BcaA. Further
studies will include characterization of these polypeptides and de-
termining if these polypeptides are generated by autoproteolysis
or if another protein is involved in processing.
We showed that bcaA and bcaB are required for invasion and
plaque formation in epithelial cells but did not affect uptake in
phagocytic cells. B. pseudomallei has been shown to invade and
replicate in both phagocytic and nonphagocytic cells and to
spread from cell to cell without leaving the cytoplasm (17). Al-
though a substantial amount has been learned about the intracel-
lular life cycle of B. pseudomallei, no proteins responsible for the
initial invasion step have been identified previously. BcaA, there-
fore, represents the first identified invasin in B. pseudomallei.
In vivo, bcaA is required for efficient dissemination to or sur-
vival of B. pseudomallei in the spleen in a BALB/c intranasal model
of infection. Although histology showed no difference in the
FIG 6 Histological analysis of B. pseudomallei-infected tissues. Representative tissue samples from BALB/c mice infected i.n. with Bp340 or the Bp340bcaA and
Bp340bcaA::attTn7bcaA strains (500 CFU) or from mock (PBS)-infected control animals are shown.
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amounts of inflammatory foci found in the spleens of animals
infected with the Bp340bcaA strain and in those of animals in-
fected with the wild-type strain, significantly fewer bacteria were
recovered from the spleens of animals infected with the
Bp340bcaA strain. How the invasion phenotype in vitro relates to
the spleen dissemination or survival defect in vivo is unknown.
Yersinia enterocolitica has been shown to have both invasin-de-
pendent and invasin-independent routes of spleen colonization
from the intestine of C57BL/6 mice; Handley et al. showed that a
Y. enterocolitica invasin mutant was attenuated in its ability to
disseminate from the intestine to the spleen (35). The same phe-
notype has also been described for Y. pseudotuberculosis after oral
inoculation (36). It had been proposed that enteropathogenic Yer-
sinia bacteria colonize the Payer’s patch and then drain into the
mesenteric lymph nodes and, in turn, enter tissues such as the
spleen. The studies by Marra et al. and Handley et al., however,
showed that there are several routes of spread, and how initial
colonization of one site leads to the colonization of another ap-
pears to be more complicated than initially appreciated. To date,
little is known about how B. pseudomallei disseminates from the
initial site of infection (37). Inhalation, ingestion, and soft tissue
abrasions or lacerations are routes of infection (6, 38); however,
the steps the bacteria follow after the inoculation are still un-
known. It is possible that bcaA functions like the Y. enterocolitica
invasin, specifically aiding dissemination to the spleen. Further
studies will include determining the route of spleen colonization,
as well as determining if bcaA and bcaB affect survival once the
bacteria have reached the spleen.
bcaB is predicted to encode a hypothetical protein with a prolyl
4-hydroxylase domain. Bacterial prolyl 4-hydroxylases are be-
lieved to hydroxylate peptidyl prolines, and although some such
hydroxylases have been identified in bacteria, their substrates and
therefore their function remain unknown (39). Prolyl 4-hydrox-
ylase, which catalyzes the most prevalent posttranslational modi-
fication in humans, has as the substrate collagen, functioning by
stabilizing the collagen triple-helix structure (40), elastin, where it
affects the formation of elastin fibrils (41), and even prion pro-
teins, although the consequences of the presence of the prion pro-
teins are unknown (39). In bacteria, a Bacillus anthracis enzyme
designated anthrax-P4H has been shown to hydroxylate peptidyl
prolines; however, although it binds to collagen-like peptides in
vitro, its physiological substrate and role remain unknown (42).
Further studies should include determining if bcaB plays a role in
hydroxylating any of the 52 prolines found in BcaA, since it is
possible that BcaA is the physiological substrate for BcaB, which
would be consistent with their operon structures.
Both bcaA and bcaB are required for invasion and plaque for-
mation, consistent with the idea that they function together. How-
ever, only bcaA showed a phenotype in vivo. It is possible that this
simply reflects the limitations of the tools we used. Although the
BALB/c model has been broadly used as an acute model for B.
pseudomallei infection (43), it may not be sensitive enough to
reveal phenotypes for all factors that contribute to disease, de-
pending on the step and stage of disease in which they function.
Our future experiments will include the development of addi-
tional animal models that will expand the repertoire of B. pseu-
domallei disease processes that we are able to study in the labora-
tory.
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